AUTHOR=Tesfamicael Kiflu G. , Zhao Lijun , Fernández-Rodríguez Rubén , Adelson David L. , Musker Michael , Polasek Thomas M. , Lewis Martin David 

TITLE=Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis

JOURNAL=Frontiers in Psychiatry

VOLUME=Volume 15 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1276410

DOI=10.3389/fpsyt.2024.1276410

ISSN=1664-0640

ABSTRACT=Aim: To determine the efficacy and safety of pharmacogenomics (PGx)-guided antidepressant prescribing in patients with depression through an umbrella review and updated meta-analysis.Methods: A comprehensive systematic search was conducted on PsycINFO, PubMed, Embase and the Cochrane databases. The pooled effect sizes of randomised controlled trials (RCTs) were expressed as mean differences for continuous data and risk ratios for noncontinuous data.Results: Patients who received PGx-guided medications were 41% to 78% more likely to achieve remission and 20% to 49% more likely to respond to antidepressants than patients receiving treatment-as-usual (TAU). Conclusion: PGx-guided antidepressant prescribing improves the treatment of depression. However, the significance and magnitude of the benefit varies widely between studies and different PGx testing panels.